Breast cancer is the most common form of cancer affecting women (other than skin cancer), and is the second leading cause of cancer mortality among women. About 213,000 new cases of breast cancer will be diagnosed in 2006.
In recent years, newer endocrine therapies have been developed for breast cancer. Adjuvant use of aromatase inhibitors, for example, are among the most promising, joining therapeutic options such as tamoxifen, and providing additional alternatives that may improve long-term survival. Large randomized trials in postmenopausal women with hormone receptor positive breast cancer have demonstrated the benefits of third-generation aromatase inhibitors upon patient outcomes.
In this important and unique one-hour program for clinicians involved in the management of breast cancer, a leading expert will discuss the latest research and state-of-the-art thinking in this rapidly evolving field. Along with an examination of recent developments in adjuvant treatment, the faculty will describe key factors to consider in clinical decision-making in patient subsets, and will look at what is on the horizon. After hearing a didactic presentation on this topic, audience members will have the opportunity to participate in a question and answer session that will help them apply this information to their own practices.